Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Kyverna Therapeutics and Relay Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyverna Therapeutics | 0 | 1 | 4 | 1 | 3.00 |
| Relay Therapeutics | 0 | 1 | 9 | 0 | 2.90 |
Kyverna Therapeutics currently has a consensus price target of $18.40, indicating a potential upside of 636.00%. Relay Therapeutics has a consensus price target of $19.80, indicating a potential upside of 440.98%. Given Kyverna Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than Relay Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Kyverna Therapeutics | N/A | -51.12% | -37.91% |
| Relay Therapeutics | N/A | -45.75% | -40.75% |
Earnings & Valuation
This table compares Kyverna Therapeutics and Relay Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyverna Therapeutics | $7.03 million | 15.35 | -$60.37 million | N/A | N/A |
| Relay Therapeutics | $10.01 million | 62.00 | -$341.97 million | ($2.39) | -1.53 |
Kyverna Therapeutics has higher earnings, but lower revenue than Relay Therapeutics.
Insider and Institutional Ownership
18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Relay Therapeutics beats Kyverna Therapeutics on 6 of the 11 factors compared between the two stocks.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
About Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
